These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28541510)

  • 1. Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens.
    Taubert M; Zander J; Frechen S; Scharf C; Frey L; Vogeser M; Fuhr U; Zoller M
    J Antimicrob Chemother; 2017 Aug; 72(8):2304-2310. PubMed ID: 28541510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients.
    Dong H; Xie J; Wang T; Chen L; Zeng X; Sun J; Wang X; Dong Y
    Int J Antimicrob Agents; 2016 Sep; 48(3):259-64. PubMed ID: 27474469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is continuous infusion of imipenem always the best choice?
    Suchánková H; Lipš M; Urbánek K; Neely MN; Strojil J
    Int J Antimicrob Agents; 2017 Mar; 49(3):348-354. PubMed ID: 28189734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
    Kim A; Kuti JL; Nicolau DP
    Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment.
    Barrasa H; Soraluce A; Isla A; Martín A; Maynar J; Canut A; Sánchez-Izquierdo JA; Rodríguez-Gascón A
    J Crit Care; 2019 Apr; 50():69-76. PubMed ID: 30496913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
    Eagye KJ; Kuti JL; Dowzicky M; Nicolau DP
    Clin Ther; 2007 May; 29(5):889-899. PubMed ID: 17697907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.
    Minichmayr IK; Schaeftlein A; Kuti JL; Zeitlinger M; Kloft C
    Clin Pharmacokinet; 2017 Jun; 56(6):617-633. PubMed ID: 27753002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
    Ulldemolins M; Roberts JA; Wallis SC; Rello J; Lipman J
    J Antimicrob Chemother; 2010 Aug; 65(8):1771-8. PubMed ID: 20530507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged infusion of linezolid is associated with improved pharmacokinetic/pharmacodynamic (PK/PD) profiles in patients with external ventricular drains.
    Zhao W; Kong L; Wu C; Wu X
    Eur J Clin Pharmacol; 2021 Jan; 77(1):79-86. PubMed ID: 32812063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
    Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
    Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients.
    Taubert M; Zoller M; Maier B; Frechen S; Scharf C; Holdt LM; Frey L; Vogeser M; Fuhr U; Zander J
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5254-61. PubMed ID: 27324768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study.
    Wang X; Wang Y; Yao F; Chen S; Hou Y; Zheng Z; Luo J; Qiu B; Li Z; Wang Y; Wu Z; Lan J; Chen C
    Drug Des Devel Ther; 2021; 15():2129-2141. PubMed ID: 34040351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
    J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.
    Millard J; Pertinez H; Bonnett L; Hodel EM; Dartois V; Johnson JL; Caws M; Tiberi S; Bolhuis M; Alffenaar JC; Davies G; Sloan DJ
    J Antimicrob Chemother; 2018 Jul; 73(7):1755-1762. PubMed ID: 29584861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
    Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
    Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of linezolid treatment regimens for Gram-positive bacterial infections based on pharmacokinetic/pharmacodynamic analysis.
    Yang M; Zhang J; Chen Y; Liang X; Guo Y; Yu J; Zhu D; Zhang Y
    Future Microbiol; 2017 Jan; 12():39-50. PubMed ID: 27922745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.